NASDAQ:MYNZ Mainz Biomed (MYNZ) Stock Price, News & Analysis $0.24 0.00 (0.00%) (As of 11/5/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrends About Mainz Biomed Stock (NASDAQ:MYNZ) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Mainz Biomed alerts:Sign Up Key Stats Today's Range$0.23▼$0.2550-Day Range$0.20▼$0.3952-Week Range$0.19▼$3.39Volume1.14 million shsAverage Volume925,556 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice Target$3.00Consensus RatingModerate Buy Company OverviewMainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.Read More… Watch this before it gets removed (Ad)If you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Mainz Biomed Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks43rd Percentile Overall ScoreMYNZ MarketRank™: Mainz Biomed scored higher than 43% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingMainz Biomed has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageMainz Biomed has received no research coverage in the past 90 days.Read more about Mainz Biomed's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Mainz Biomed is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mainz Biomed is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMainz Biomed has a P/B Ratio of 0.88. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Mainz Biomed's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted9.74% of the float of Mainz Biomed has been sold short.Short Interest Ratio / Days to CoverMainz Biomed has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Mainz Biomed has recently decreased by 25.11%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMainz Biomed does not currently pay a dividend.Dividend GrowthMainz Biomed does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted9.74% of the float of Mainz Biomed has been sold short.Short Interest Ratio / Days to CoverMainz Biomed has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Mainz Biomed has recently decreased by 25.11%, indicating that investor sentiment is improving significantly. News and Social Media0.0 / 5News SentimentN/A Search InterestOnly 3 people have searched for MYNZ on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company OwnershipN/AInsider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Mainz Biomed insiders have not sold or bought any company stock.Read more about Mainz Biomed's insider trading history. Receive MYNZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mainz Biomed and its competitors with MarketBeat's FREE daily newsletter. Email Address MYNZ Stock News HeadlinesEQS-News: Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate UpdateOctober 22, 2024 | markets.businessinsider.comMainz Biomed restructured operations, implemented cost reductionsOctober 21, 2024 | markets.businessinsider.comThe most serious warning of my careerWith the 2024 election just weeks away, a new crisis is barrelling down on America… one that could cleave the financial world in two the moment the polls close. I predict they could see investment losses of 50% (or more) in the weeks following the presidential election. November 5, 2024 | Porter & Company (Ad)Mainz Biomed Highlights Growth and Innovations for 2025October 21, 2024 | markets.businessinsider.comMainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate UpdateOctober 21, 2024 | globenewswire.comMainz Biomed Secures Additional $1.5M FundingOctober 10, 2024 | finance.yahoo.comMainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New VersionOctober 8, 2024 | globenewswire.comMainz Biomed $MYNZ Introduces The Newest Addition To Their TeamOctober 4, 2024 | msn.comSee More Headlines MYNZ Stock Analysis - Frequently Asked Questions How have MYNZ shares performed this year? Mainz Biomed's stock was trading at $1.16 at the beginning of the year. Since then, MYNZ stock has decreased by 79.6% and is now trading at $0.2367. View the best growth stocks for 2024 here. How were Mainz Biomed's earnings last quarter? Mainz Biomed (NASDAQ:MYNZ) released its quarterly earnings data on Tuesday, August, 15th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.42) by $0.14. The company had revenue of $0.25 million for the quarter, compared to analyst estimates of $0.25 million. When did Mainz Biomed IPO? Mainz Biomed (MYNZ) raised $10 million in an initial public offering on Friday, November 5th 2021. The company issued 2,000,000 shares at $4.00-$6.00 per share. Boustead Securities served as the underwriter for the IPO. How do I buy shares of Mainz Biomed? Shares of MYNZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Mainz Biomed own? Based on aggregate information from My MarketBeat watchlists, some other companies that Mainz Biomed investors own include Sangamo Therapeutics (SGMO), Meta Platforms (META), NVIDIA (NVDA), Ford Motor (F), Advanced Micro Devices (AMD), Enterprise Products Partners (EPD) and PayPal (PYPL). Company Calendar Last Earnings8/15/2023Today11/05/2024Next Earnings (Estimated)11/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MYNZ CUSIPN/A CIK1874252 Webmainzbiomed.com Phone49-6131-554-2860FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Stock Price Target$3.00 High Stock Price Target$3.00 Low Stock Price Target$3.00 Potential Upside/Downside+1,146.9%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.24 Quick Ratio0.19 Sales & Book Value Annual Sales$900,000.00 Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.27 per share Price / Book0.89Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta0.07 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:MYNZ) was last updated on 11/5/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trad...Investing Daily | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredNASDAQ small cap that could be gearing up for a massive short squeeze.A Heavy Short Interest Could Lead to a Monstrous Short Squeeze for this Tiny NASDAQ Healthcare Firm!Huge Alerts | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mainz Biomed Please log in to your account or sign up in order to add this asset to your watchlist. Share Mainz Biomed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.